Stockscreener 앱 받기
22.47
0.65%
-0.1504
전일 마감가:
$22.62
열려 있는:
$22.61
하루 거래량:
537.89K
Relative Volume:
0.22
시가총액:
$2.87B
수익:
$631.73M
순이익/손실:
$-239.78M
주가수익비율:
-11.12
EPS:
-2.02
순현금흐름:
$-33.45M
1주 성능:
+14.31%
1개월 성능:
+17.91%
6개월 성능:
+65.61%
1년 성능:
+113.62%
1일 변동 폭
$22.30
$23.09
1주일 범위
$19.66
$23.30
52주 변동 폭
$6.78
$23.56
10X 제노믹스 Stock (TXG) Company Profile
명칭
10 X Genomics Inc
전화
(925) 401-7300
주소
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, TEM, BTSG, HQY, WAY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
22.45 | 2.89B | 631.73M | -239.78M | -33.45M | -2.02 |
|
VEEV
Veeva Systems Inc
|
186.46 | 30.56B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
51.90 | 9.19B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
41.59 | 7.33B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
82.79 | 6.87B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
26.36 | 5.09B | 906.14M | -52.62M | 89.62M | -0.3621 |
10X 제노믹스 Stock (TXG) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-12-02 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-09-11 | 개시 | Piper Sandler | Neutral |
| 2025-02-13 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-03 | 개시 | Leerink Partners | Outperform |
| 2024-07-22 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-07-18 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-10 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2024-06-27 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2024-06-03 | 재개 | Jefferies | Hold |
| 2024-05-01 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-12-12 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2023-07-05 | 재개 | JP Morgan | Overweight |
| 2023-05-10 | 개시 | Barclays | Overweight |
| 2023-03-31 | 개시 | Stephens | Overweight |
| 2023-02-02 | 개시 | UBS | Neutral |
| 2022-12-14 | 개시 | Deutsche Bank | Buy |
| 2022-08-18 | 다운그레이드 | Goldman | Neutral → Sell |
| 2022-07-25 | 개시 | Canaccord Genuity | Buy |
| 2022-07-15 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-15 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | 재개 | Cowen | Outperform |
| 2021-09-14 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-15 | 개시 | William Blair | Outperform |
| 2020-12-02 | 개시 | Goldman | Neutral |
| 2020-09-09 | 개시 | Morgan Stanley | Overweight |
| 2020-07-10 | 개시 | Stifel | Buy |
| 2020-03-05 | 개시 | Guggenheim | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-10-07 | 개시 | BofA/Merrill | Buy |
| 2019-10-07 | 개시 | Cowen | Outperform |
| 2019-10-07 | 개시 | JP Morgan | Overweight |
| 2019-09-24 | 개시 | Evercore ISI | Outperform |
모두보기
10X 제노믹스 주식(TXG)의 최신 뉴스
10x Genomics $TXG Position Lifted by Vanguard Group Inc. - MarketBeat
Breaking Down 10x Genomics: 11 Analysts Share Their Views - Sahm
Commit To Buy 10x Genomics At $15, Earn 20.6% Annualized Using Options - Nasdaq
TXG Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: A Closer Look at the Healthcare Innovator’s Growth Potential and Analyst Ratings - DirectorsTalk Interviews
Major RSU grant to 10x Genomics (TXG) CEO Serge Saxonov - Stock Titan
88,816 RSUs awarded to 10x Genomics (TXG) director Hindson - Stock Titan
10x Genomics (TXG) CFO granted 106,579 RSUs in new equity award - Stock Titan
TXG affiliate files Form 144: proposed Class A Common sale (NASDAQ: TXG) - Stock Titan
10X Genomics Hits Day High with Strong 12.56% Intraday Surge - Markets Mojo
10X Genomics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Is It Time To Reassess 10x Genomics (TXG) After Its 1 Year Share Price Surge - Yahoo Finance
Is 10x Genomics Inc.’s ROIC above industry averageTrade Performance Summary & AI Driven Price Forecasts - mfd.ru
Insider Sell: Sarah Teichmann Sells Shares of 10x Genomics Inc (TXG) - GuruFocus
Director at 10x Genomics (TXG) sells 7,579 shares under 10b5-1 plan - Stock Titan
10x Genomics (TXG) Price Target Increased by 10.28% to 20.33 - Nasdaq
10x Genomics (NASDAQ:TXG) CEO Serge Saxonov Sells 9,632 Shares of Stock - MarketBeat
10x Genomics (TXG) CEO sells 9,632 shares to cover RSU tax - Stock Titan
[Form 4] 10x Genomics, Inc. Insider Trading Activity - Stock Titan
10x Genomics (TXG) officer sells 7,826 shares to cover RSU tax - Stock Titan
10x Genomics, Inc. (TXG) Stock Analysis: Navigating Growth Potential In Health Information Services - DirectorsTalk Interviews
Vestmark Advisory Solutions Inc. Sells 340,854 Shares of 10x Genomics $TXG - MarketBeat
Insider sale filing for TXG (NASDAQ: TXG) lists 8,301 shares on 02/23/2026 - Stock Titan
TXG (NASDAQ: TXG) insider sale notice: 25,784 RSU shares listed for sale - Stock Titan
Issuer insider sale notice — 23,767 shares (NASDAQ: TXG) - Stock Titan
Is 10x Genomics Inc. (1KJ) stock positioned for secular growthRecession Risk & Expert Curated Trade Ideas - mfd.ru
TXG: UBS Raises Price Target for 10x Genomics to $20 | TXG Stock News - GuruFocus
10x Genomics to Participate in the 46th Annual TD Cowen Health Care Conference - BioSpace
5 Must-Read Analyst Questions From 10x Genomics's Q4 Earnings Call - Finviz
GSA Capital Partners LLP Buys 106,167 Shares of 10x Genomics $TXG - MarketBeat
162,202 Shares in 10x Genomics $TXG Bought by Principal Financial Group Inc. - MarketBeat
10x Genomics Stock Climbs as Analysts Signal Growth Prospects - StocksToTrade
10x Genomics’ Growth Prospects Brightened by Strategic Advances - timothysykes.com
10x Genomics Cancer Alliances Test AI Ambitions Against Mixed Share Performance - Yahoo Finance
10x Genomics Sees Bullish Momentum Following Revenue Projections and Price Target Upgrades - StocksToTrade
10x Genomics Sees Bullish Momentum with Raised Price Targets - timothysykes.com
Is 10x Genomics Inc. still a buy after recent gains2025 Biggest Moves & AI Forecast Swing Trade Picks - mfd.ru
Decoding 10x Genomics Inc (TXG): A Strategic SWOT Insight - GuruFocus
Earnings Call Summary | 10x Genomics(TXG.US) Q4 2025 Earnings Conference - 富途牛牛
Expert Outlook: 10x Genomics Through The Eyes Of 10 Analysts - Benzinga
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity - Investing.com UK
Why Is 10x Genomics (TXG) Stock Soaring Today - Finviz
10X Genomics stock price target raised to $22 from $20 at Canaccord Genuity By Investing.com - Investing.com India
10x Genomics (NASDAQ:TXG) Shares Gap Up on Earnings Beat - MarketBeat
10x Genomics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
10x Genomics, Inc. (NASDAQ:TXG) Q4 2025 Earnings Call Transcript - Insider Monkey
10x Genomics Q4 Earnings Call Highlights - MarketBeat
10x Genomics, Inc. SEC 10-K Report - TradingView
10x Genomics: Fourth Quarter Financial Overview - Bitget
10x Genomics Inc (TXG) Q4 2025 Earnings Call Highlights: Surpass - GuruFocus
Can 10x Genomics Inc. stock outperform in a bear market2025 Top Decliners & High Return Trade Opportunity Guides - mfd.ru
10X 제노믹스 (TXG) 재무 분석
매출
순이익
현금흐름
주당 순 이익
10X 제노믹스 주식 (TXG) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Teichmann Sarah A. | Director |
Feb 25 '26 |
Sale |
19.41 |
7,579 |
147,108 |
26,780 |
| Saxonov Serge | Chief Executive Officer |
Feb 23 '26 |
Sale |
18.58 |
9,632 |
178,928 |
1,061,924 |
| Taich Adam | Chief Financial Officer |
Feb 23 '26 |
Sale |
18.58 |
8,968 |
166,593 |
288,417 |
| Hindson Benjamin J. | See Remarks |
Feb 23 '26 |
Sale |
18.58 |
7,826 |
145,379 |
424,779 |
0.50%
2.32%
자본화:
|
볼륨(24시간):